Evidence map›Paper›PMID 38892177›Full record

ArticleInternational journal of molecular sciences2024

High-Yield α-Synuclein Purification and Ionic Strength Modification Pivotal to Seed Amplification Assay Performance and Reproducibility.

Chelva Janarthanam, Griffin Clabaugh, Zerui Wang, Bradley R Melvin, Ileia Scheibe, Huajun Jin, Vellareddy Anantharam, Ramona J B Urbauer, Jeffrey L Urbauer, Jiyan Ma and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chelva JanarthanamCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Griffin ClabaughCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Zerui WangDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Bradley R MelvinDepartment of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA.
Ileia ScheibeCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Huajun JinCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Vellareddy AnantharamCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Ramona J B UrbauerDepartment of Chemistry, University of Georgia, Athens, GA 30602, USA.
Jeffrey L UrbauerDepartment of Chemistry, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0001-5722-6674
Jiyan MaChinese Institute for Brain Research, Beijing 102206, China.
Arthi KanthasamyCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.
Xuemei HuangDepartment of Neurology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Vincenzo DonadioIRCCS Institute of Neurological Sciences of Bologna, Complex Operational Unit Clinica Neurologica, 40138 Bologna, Italy.
Wenquan ZouDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Anumantha G KanthasamyCenter for Neurological Disease Research, Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602, USA.

Funding

Regional Brain Manganese Accumulation and Functional Consequences in WeldersR01ES019672 · NIEHS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI · 2011 to 2021
$5.9M
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological RelevanceU01NS112008 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI, KANTHASAMY, ANUMANTHA GOUNDER · 2019 to 2023
$5.5M
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD ParkinsonismU01NS112010 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., GUNZLER, STEVEN A. · 2019 to 2023
$3.7M
Role of skin prions in disease transmission and diagnostic testing of human prion diseaseR01NS109532 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI KONG, QINGZHONG · 2018 to 2022
$2.9M
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body DementiasR01NS118669 · NINDS · BANNER HEALTH · PI ADLER, CHARLES H, BEACH, THOMAS G · 2021 to 2024
$2.3M
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.R01ES026892 · NIEHS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2016 to 2020
$2.0M
National Institutes of Health/National Institute of Neurological Disorders and Stroke NS109532National Institutes of Health/National Institute of Neurological Disorders and Stroke NS112008National Institutes of Health/National Institute of Neurological Disorders and Stroke NS112010NIEHS NIH HHS R01 ES019672NIEHS NIH HHS R01 ES026892NIH HHS ES026892NIH HHS NS118669NINDS NIH HHS R01 NS109532NINDS NIH HHS R01 NS118669NINDS NIH HHS U01 NS112008NINDS NIH HHS U01 NS112010The Michael J. Fox Foundation MJFF-020781The Michael J. Fox Foundation MJFF-021089United States Department of Defense W81XWH2010781
6 · The paper itself

Abstract

Alpha-synuclein seed amplification assays (αSyn-SAAs) have emerged as promising diagnostic tools for Parkinson's disease (PD) by detecting misfolded αSyn and amplifying the signal through cyclic shaking and resting in vitro. Recently, our group and others have shown that multiple biospecimens, including CSF, skin, and submandibular glands (SMGs), can be used to seed the aggregation reaction and robustly distinguish between patients with PD and non-disease controls. The ultrasensitivity of the assay affords the ability to detect minute quantities of αSyn in peripheral tissues, but it also produces various technical challenges of variability. To address the problem of variability, we present a high-yield αSyn protein purification protocol for the efficient production of monomers with a low propensity for self-aggregation. We expressed wild-type αSyn in BL21

Indexed as

alpha-SynucleinParkinson DiseaseEscherichia coliHumansOsmolar ConcentrationReproducibility of Resultsalpha-SynucleinSNCA protein, humanParkinson’s diseasepathological α-synucleinseed amplification assay (SAA)αSyn

Identifiers

PMID38892177
PMCPMC11172462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.